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ABSTRACT
End-stage kidney disease represents irreversible kidney failure. Dialysis and 
transplantation, two main treatment options currently available, present various 
drawbacks and complications. Innovative cell-based therapies, such as a bioartificial 
kidney, have not reached the clinic yet, mostly due to safety and/or functional 
issues. Here, we assessed the safety of conditionally immortalized proximal tubule 
epithelial cells (ciPTECs) for bioartificial kidney application, by using in vitro assays 
and athymic nude rats. We demonstrate that these cells do not possess key properties 
of oncogenically transformed cells, including anchorage-independent growth, 
lack of contact inhibition and apoptosis-resistance. In late-passage cells we did 
observe complex chromosomal abnormalities favoring near-tetraploidy, indicating 
chromosomal instability. However, time-lapse imaging of ciPTEC-OAT1, confined to a 
3D extracellular matrix (ECM)-based environment, revealed that the cells were largely 
non-invasive. Furthermore, we determined the viral integration sites of SV40 Large 
T antigen (SV40T), human telomerase (hTERT) and OAT1 (SLC22A6), the transgenes 
used for immortalization and cell function enhancement. All integrations sites were 
found to be located in the intronic regions of endogenous genes. Among these genes, 
early endosome antigen 1 (EEA1) involved in endocytosis, and BCL2 Like 1 (BCL2L1) 
known for its role in regulating apoptosis, were identified. Nevertheless, both gene 
products appeared to be functionally intact. Finally, after subcutaneous injection in 
athymic nude rats we show that ciPTEC-OAT1 lack tumorigenic and oncogenic effects 
in vivo, confirming the in vitro findings. Taken together, this study lays an important 
foundation towards bioartificial kidney (BAK) development by confirming the safety 
of the cell line intended for incorporation. 
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INTRODUCTION
End-stage kidney disease (ESKD) represents 
irreversible kidney failure through a variety of 
causes. Ageing of the population, with frequently 
occurring diabetes, atherosclerotic vascular disease, 
and hypertension, is predominantly responsible for 
an increasing prevalence of ESKD [1–3]. Despite the 
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large socioeconomic impact of ESKD [4], innovative 
novel therapies have thus far failed to reach the clinic. 
Recognition of the problems related to currently available 
treatments,  has spurred the development of novel 
approaches of which cell-based systems, also known 
as bioartificial kidney (BAK), that seek to replicate the 
kidney’s function through the integration of proximal 
tubule cells are of promise [5]. 
One of the crucial issues to take into consideration 
when developing a BAK is the sufficient availability of 
suitable cells. Human primary proximal tubule epithelial 
cells (PTEC) have a limited life span in vitro and 
presenting risks, such as functional changes occurring 
upon culturing as well as dedifferentiation and senescence 
of cells [6, 7]. Several studies have therefore focused on 
animal cells [8–10], or cell lines [11–15]. Issues related 
to the use of animal-derived cells in BAK are safety 
concerns compromising approval for clinical application 
and species differences in cell behaviour. 
To overcome these limitations, we employed human 
urine-derived PTEC that were conditionally immortalized 
using the essential catalytic subunit of human telomerase 
(hTERT) and a temperature-sensitive mutant U19tsA58 
of SV40 large T antigen (SV40T), creating conditionally 
immortalized PTEC (ciPTEC) [16]. Due to the expression 
of temperature-sensitive SV40T, cells can be expanded 
at permissive temperature of 33° C and differentiated 
into mature cells at non-permissive temperature of 
37° C [16–18]. While hTERT acts by stabilizing telomeres, 
thus preventing the occurrence of replicative senescence 
[19], SV40T involves the activation of E2F-mediated 
transcription through binding with Rb-E2F complex, as 
well as the inhibition of p53 [20, 21]. The cell line has 
been thoroughly characterized over the years [16, 22–25], 
but the absence of the physiologically important organic 
anion transporter 1 (OAT1) protein led us to modify 
ciPTEC further by an overexpression of the transporter 
[26]. With this cell line we demonstrated the capacity of an 
efficient removal of uremic toxins when cells are cultured 
on hollow fiber membranes (HFM), thereby creating fully 
functional kidney tubules  [27]. In addition to the proven 
lack of ciPTEC allostimulatory potential in vitro [28], a 
successful upscaling of the biofunctionalized HFM with 
tight epithelial monolayers and cell function has been 
achieved, encouraging further efforts towards the BAK 
development [29]. 
Eyeing possible clinical applications of ciPTEC, 
a thorough safety evaluation is warranted to exclude 
any risks related to oncogenesis and tumorigenesis [30]. 
Even though SV40T mediated inhibition of p53 and Rb 
pathways or telomere length maintenance by hTERT are 
not sufficient to induce oncogenic transformation, various 
parameters related to cell growth and proliferation, 
apoptosis and migration have to be examined [31–35]. 
Given that the transgenes were introduced by retroviral 
and lentiviral transductions, which can be oncogenic 
through insertional mutagenesis [36–38], we evaluated if 
the transgenes had disrupted proto-oncogenes or important 
genes required for PTEC function. Finally, we evaluated 
cell transforming properties and tumorigenic potential 
in vivo to gain more insight into safety and suitability of 
these cells for applications in renal replacement therapies. 
RESULTS
The proliferative capacity and apoptosis 
resistance of ciPTEC in relation to SV40T 
expression
As expected [16], the expression of SV40T was 
abundant at permissive temperature (33° C) but went 
down (90% reduction) within one day of culturing at a 
non-permissive temperature (37° C) and remained low 
for up to 7 days  (Figure 1A). Clinical studies indicated 
that cooling the dialysate down to 35° C can be beneficial 
as it may enhance the patient’s hemodynamic stability by 
preventing intradialytic hypotension [39, 40]. A transient 
drop in temperature (4 h, 33° C), however, did not result 
in an increase in SV40T expression compared to cells 
maintained at 37° C for 7 days (Figure 1A). 
In a subconfluent state a higher proportion of cells 
was found in S-phase at the permissive temperature 
(Figure 1B; 40.5% ± 1.7%) compared to 37° C for 1 day 
(10.5% ± 2.0%) or 7 days (17.0% ± 3.4%), confirming 
that SV40T protein expression is directly related to 
cell proliferation. At full confluency (Figure 1C), the 
same trend was observed with a higher proportion of 
proliferating cells at the permissive (20.4% ± 1.9%) 
compared to the non-permissive temperature (6.3% ± 
6.9% after 1 day at 37° C and 12.1% ± 1.5% after 7 days 
at 37° C). 
Following 24 h of exposure to nutlin-3a to trigger 
p53-mediated apoptosis, one of the main targets of SV40T 
[20], matured cells expressing lower levels of SV40T 
displayed higher sensitivity to nutlin-3a compared to 
cells cultured at permissive temperature. Indeed, cells 
at 33° C were resistant to nutlin-3a-induced cell death, 
whereas cells at 37° C showed reduced cell viability and 
higher expression of caspase-3/7 even at lower nutlin-3a 
concentrations (Figure 1D–1E). 
CiPTEC-OAT1 obey the rule of contact-
inhibition
Further, ciPTEC-OAT1 growth did not extend 
beyond a confluent epithelial monolayer regardless of 
permissive or non-permissive temperature (Figure 2A), 
indicating contact inhibition. In contrast, HeLa cells 
presented multi-layered growth with >55% of growth 
surface covered with multiple cell layers when cultured 
at 33° C, and ~70% of multi-layered cell growth at 37° C 
(Figure 2B–2C). When ciPTEC-OAT1 were cultured on 
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Figure 1: Temperature-dependent effect of SV40T expression on ciPTEC-OAT1 proliferation and apoptosis-sensitivity. 
(A) Western blot analysis of SV40T levels in ciPTEC-OAT1 cultured at the permissive (33° C) temperature and the non-permissive (37° C) 
temperature for 1 day, 7 days or 7 days followed by a 4 h incubation at 33° C (switch). Intensity of the bands was normalized to GAPDH and 
quantification is depicted in the bar graph. Human kidney tissue protein sample served as control. Representative histograms and analysis 
of cell cycle distribution of ciPTEC-OAT1 cultured at (B) subconfluent and (C) confluent levels at 33° C and 37° C for 1 day, 7 days or 7 
days followed by 4 h at 33° C (switch). (D) Cell viability analysis and (E) caspase-3/7 expression in ciPTEC-OAT1 cultured at 33° C and 
37° C and exposed to increasing concentrations of nutlin-3a for 24 h.  All values are expressed as the mean ± SEM of three independent 
experiments performed in triplicate. *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired two-tailed Student’s t-test and one-way ANOVA followed 
by Dunnett’s multiple comparison test).
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HFM, multi-layered growth was also not observed at both 
temperatures (Figure 2D). 
CiPTEC-OAT1 require anchorage for 
proliferation 
Anchorage-independent growth is a hallmark of 
cancer cells [41, 42], and it is assessed using the soft 
agar assay (Figure 3A). Single cells were encapsulated 
in semi-solid agarose medium thereby creating an 
environment lacking anchorage means (i.e. cell-cell and 
cell-extracellular matrix (ECM) interactions). After 4 
weeks of culture, sporadic colony formation was observed 
for ciPTEC-OAT1 (0.87 ± 0.21 colonies per field (CPF)) 
compared to control HeLa cells (12.70 ± 0.58 CPF). 
Similarly, colonies were absent in cultures of mature 
Figure 2: Contact inhibition in ciPTEC-OAT1. (A) Schematic diagram of focus formation assay. CiPTEC-OAT1 were cultured in 
2D (96-well microplate) and 3D (hollow fiber membranes; HFM) for 28 days at 33° C and 37° C. HeLa cells were cultured in 2D in same 
conditions. Foci (multi-layered growth) formation was detected by nuclear staining and confocal imaging and (B) representative depth-
coded images of nuclei-stained ciPTEC-OAT1 and HeLa cells after 28 days of culture at both permissive and non-permissive temperature 
are shown. Scale bars denote 200 µm in the original image and 100 µm in the zoom-in. (C) Quantification of the surface area covered by 
multi-layered proliferation). ND = not detected. (D) Representative confocal images of nuclei stained ciPTEC-OAT1 cultured on double-
coated HFM at 33° C and 37° C, x-y confocal planes on the upper part and y-z confocal planes on the bottom part. Images taken with 10× 
magnification. Scale bar: 50 μm. Values are expressed as the mean ± SEM of three independent experiments performed in triplicate. ***p < 
0.001 (unpaired two-tailed Student’s t-test).
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ciPTEC-OAT1 (0.07 ± 0.05 CPF) while abundantly 
present in cultures of HeLa cells (15.10 ± 0.95 CPF) 
(Figure 3B). Qualitatively, colonies incidentally observed 
in ciPTEC-OAT1 cultures were much smaller than in 
HeLa cell cultures (Figure 3C), as also illustrated by the 
macroscopic images (Figure 3D), where only HeLa cells 
formed colonies at 37° C large enough to be visible by eye. 
CiPTEC-OAT1 are predominantly non-invasive 
A cell-tracking experiment in growth factor 
reduced Matrigel™ was performed to model invasive and 
metastatic capacity of matured ciPTEC-OAT1 in vitro. 
During a 24 h time-lapse, the majority of cells (89.0%) 
did not migrate and remained non-invasive (Figure 4A, 
Figure 3: Anchorage-independent growth at permissive and non-permissive temperatures. (A) Schematic diagram of soft 
agar assay. Single ciPTEC-OAT1 and HeLa cells were seeded in agarose-containing medium (0.3% (w/v)) and incubated for 28 days at 
either 33° C or 37° C. Cell growth and colony formation was detected by confocal imaging. (B) Quantification of colonies detected for 
ciPTEC-OAT1 and HeLa cells presented as number of colonies per field. (C) Representative microscopic pictures of cell colonies formed 
by ciPTEC-OAT1 HeLa cells after 28 days culture at 33° C and 37° C. Scale bars denote 50 µm. (D) Representative macroscopic pictures of 
ciPTEC-OAT1 and HeLa cell colonies. Scale bar denotes 1 cm. Values are expressed as the mean ± SEM of three independent experiments 
performed in triplicate. ***p < 0.001 (unpaired two-tailed Student’s t-test).
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Supplementary Figure 1). However, a small population 
was able to migrate through the ECM. Morphologically, 
these cells showed mesenchymal cell-like features and 
moved accordingly with a speed higher than 6 μm/h, 
whereas non-invading cells remained round-shaped with 
minimal movement within their own space at a speed 
below 6 μm/h (Figure 4B, 4C). 
Transgene integration sites and genomic stability
Next, we evaluated the integration sites of the 
genes encoding for SV40T, hTERT and OAT1 and their 
consequences for ciPTEC-OAT1. For this, TLA was 
utilized to amplify the transgenes and their surrounding 
regions, from which precise integration sites were mapped 
(Figure 5A). We identified integrations sites located in 
the intronic regions of six endogenous genes. SV40T 
was integrated in GNA12 (chromosome 7) (Figure 5B; 
Supplementary Figure 2A, 2C) and BCL2L1 (chromosome 
20) (Supplementary Figure 2B, 2C). The hTERT was 
stably integrated in the CAMTA1 gene (chromosome 1) 
(Supplementary Figure 3), whereas SLC22A6 (encoding 
OAT1) was integrated in WDR90 (chromosome 16), 
KIAA1958 (chromosome 9) and EEA1 (chromosome 
12) (Supplementary Figure 4). Several predictions 
were made regarding the functional consequences of 
these insertion sites (Figure 5C). Except for BCL2L1 
and EEA1, all endogenous genes are transcribed in the 
opposite direction compared to the inserted gene. A 
moderate degree of conservation was found for BCL2L1 
and CAMTA1, with phastCons 100-way scores of 0.149 
and 0.273, respectively. The other sites were classified as 
not conserved. All integration sites were analysed with 
Ensembl Variant Effect Predictor. Only BCL2L1 insertion 
site was found to be of relevance, containing both a 
regulatory-active site as well as being part of an antisense 
sequence (Figure 5C). The remaining transcript types 
were classified as low probability of being functionally 
relevant as they are either designated for degradation, such 
as nonsense-mediated decay (NMD), or the integrated 
sequence resides in a location where it would be spliced 
out.
For a final assessment of genomic abnormalities, 
ciPTEC-OAT1 at passage 52 were subjected to karyotype 
analysis. The cell population examined consisted of 68.2% 
near-tetraploid cells with the remainder being diploid. In-
depth analysis of the diploid subpopulation (Figure 5D) 
shows the prevalence of an isochromosome abnormality 
concerning the p-arm of chromosome 7, i(7)(p10), 
which occurred in 2 out of 20 diploid metaphase spreads 
examined. Further, cells were re-examined at passage 
62, where a complete shift towards near-tetraploidy was 
observed, with the presence of various complex aberrances 
among the entire cell population.
Figure 4: Migration and invasive potential of ciPTEC-OAT1. (A) Histogram showing the average speed (μm/h) at which the 
cells moved through Matrigel™ basement membrane matrix during the 24 h time-lapse imaging. Obtained values arose from 112 cells 
analyzed from two independent experiments. (B) Representative pictures showing morphological differences between the invasive and 
non-invasive phenotypes  (20× magnification). (C) Invasive cells displayed mesenchymal cell-like movement, while non-invasive cells 
were round and static, wobbled only within their own space. 
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Transgene integration does not affect endocytosis 
One of the SLC22A6 integration sites may have 
affected the function of one copy of EEA1, of which 
product, early endosome antigen (EEA1), is  involved 
in endosomal trafficking (Figure 6A), a crucial function 
in PTEC [43]. However, endosomal clusters of EEA1, 
referred to as spots (Figure 6B–6C), did not differ between 
Figure 5: Viral integration sites and chromosomal stability. (A) Chromosomal distribution of the viral integration sites of the 
SV40T, hTERT and OAT1 transgenes. (B) Schematic representation of the integration of SV40T gene into GNA12. See Supplementary 
Figures 2–4 for schematic representation of remaining affected genes. Gene legend: untranslated region (empty box), exon (filled box), 
intron (line). (C) Functional consequence prediction of the viral integration sites. Presence and absence of a specific feature is shown in 
red and grey, respectively. Legend: TI = transcriptional interference, NMD = nonsense-mediated decay, reg = regulatory features. The 
phastCons P100 database was used to identify evolutionary conserved regions. (D) Cytogenetic analysis of ciPTEC-OAT1 at passage 
number 52. Representative female karyotype of a diploid cell showing an isochromosome for the short arm of chromosome 7.
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ciPTEC-OAT1 and the control parent cell line lacking the 
EEA1-affecting integration site. This maintained EEA1 
expression was accompanied by preserved endocytosis 
function, as assessed by the uptake of fluorescently 
labelled BSA in ciPTEC-OAT1 (Figure 6B). No 
differences between EEA1 expression levels and BSA spot 
intensity were found (Figure 6D).
ciPTEC-OAT1 are not tumorigenic or oncogenic 
in vivo 
Finally, the tumorigenic and/or oncogenic potential 
ciPTEC-OAT1 were studied in vivo using nude athymic 
rats, and performed according to the World Health 
Organization (WHO) guidelines [44]. Tumorigenicity was 
Figure 6: Endocytotic capacity of ciPTEC-OAT1. (A) Schematic representation of receptor-mediated endocytosis of albumin 
by control ciPTEC and ciPTEC-OAT1, showing the integration of OAT1-encoding gene (SLC22A6) within EEA1. (B) Representative 
immunofluorescence images of EEA1 expression and endocytotic uptake of Alexa Fluor 647 labelled bovine serum albumin (BSA). Scale 
bars denote 20 µm. Quantification of the (C) EEA1 expression and (D) BSA uptake by ciPTEC-OAT1 compared to control (parent ciPTEC). 
Values are normalized against control and expressed as the mean ± SEM of three independent experiments performed in triplicate. *p < 0.05, 
**p < 0.01 (unpaired two-tailed Student’s t-test).
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evaluated by subcutaneous injection of 107 living cells, 
and oncogenicity was assessed by injection of cell lysates 
originating from the same number of cells (Figure 7A). 
HeLa cells produced palpable but not measurable nodules 
within the first week of injection in all 10 rats. Over time, 
in 6 out of 10 animals the nodules progressed into larger 
neoplastic masses that, by histological analysis, were 
confirmed to be anaplastic carcinomas in 5 out of 6 cases 
(Figure 7B, 7D). In the remaining animal, we could not 
histologically confirm carcinoma formation, most likely 
attributable to a small-sized, non-measurable neoplastic 
mass at necropsy. PCR analysis confirmed the presence of 
human specific Alu elements in all identified carcinomas, 
and also in the rat without histological evidence of 
Figure 7: Tumorigenicity and oncogenicity of ciPTEC-OAT1. (A) Schematic representation of tumorigenicity and oncogenicity 
study in vivo. A total of 107 cells (ciPTEC-OAT1 or HeLa) resuspended in 100 μl of HBSS were injected subcutaneously in the flank of the 
rats. In an additional group cell lysate derived from 107 ciPTEC-OAT1 cells and resuspended in 100 μl of HBSS was injected per animal. 
In the negative control group rats received 100 μl of the vehicle (HBSS). Following the observational period of 5 months, animals were 
sacrificed (†) and histopathological and molecular (PCR) analyses were performed to confirm tumor formation and origin, respectively. 
(B) Summary of ciPTEC-OAT1 tumorigenicity and oncogenicity study results. (C–F) Representative pictures of histopathological analysis 
of the injection sites, performed by eosin and hematoxylin staining. (C) Negative control group injection site showing normal skin with 
subcutaneous lymph node (‡) and mammary tissue (arrows). (D) Positive control group injected with HeLa cells, showing the presence 
of anaplastic carcinoma with central area of necrosis (*) expanding in subcutaneous tissue at the site of injection. (E) Experimental 
tumorigenicity group injected with ciPTEC-OAT1 cells, presenting normal skin with subcutaneous lymph node (‡) and mammary tissue 
(arrows). (F) Oncogenicity group injected with ciPTEC-OAT1 cell lysate, showing normal skin with subcutaneous lymph node (‡) and 
mammary tissue (arrows). Pictures taken at magnification 2×. (G) PCR analysis of human-specific Alu elements confirming human origin 
of identified tumors and tumor volume (mm3) at necropsy. Ct values of all tumor samples were similar to that obtained for positive control 
human genomic DNA. Both the negative control (rat genomic DNA) and blank sample produced Ct values higher than 35. Limit of the 
blank [74], defined as the highest signal expected to be found when a blank sample containing no human DNA is tested, had a Ct value of 
37.2 ± 0.71. N.M. (not measurable).
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carcinoma (Figure 7G). Importantly, the subcutaneous 
injection of HBSS (vehicle), ciPTEC-OAT1 or the cell 
lysate did not lead to nodule formation (Figure 7B–7F) and 
did not compromise animal well-being (Supplementary 
Figure 5). Analysis showed no histological lesion in the 
skin, adnexa, subcutaneous tissue and lymph nodes at 
the site of injection, nor any neoplastic formations in 
other major organs including liver, lungs, colon, spleen, 
mesenteric lymph nodes, and kidneys. This suggests that 
rats were not susceptible to spontaneous tumour formation 
and that ciPTEC-OAT1, in the given animal model, do not 
exert tumorigenic or oncogenic potential.
DISCUSSION
In the present study, we mechanistically and 
functionally confirmed that ciPTEC-OAT1 behave in 
accordance with conditional immortalization. After culture 
at non-permissive temperature they lose proliferative 
capacity and show contact inhibition. We found no 
indication for an important effect of transgene genomic 
integrations on endogenous gene expression or function. 
Although chromosomal aberrations could be demonstrated 
after multiple cell culture passages, there were no signs of 
in vivo tumorigenicity or oncogenicity.
The presence of residual SV40T, even after 7 
days of culture at the non-permissive temperature, is in 
line with the known thermolabile characteristics of the 
SV40T mutant, as it will only be completely inactivated 
above 39.5° C [18]. Furthermore, considering BAK 
application and in case of a potential temperature drop 
during hemodialysis treatment, we observed a slight, 
but not significant, rebound in SV40T expression 
after re-exposing fully matured cells for 4 h at 33° C, 
however, this has no apparent effect on cell proliferation. 
Moreover, we showed that cell proliferation is dependent 
on SV40T expression as cells maintained at permissive 
temperature were highly proliferative compared to cells 
incubated at non-permissive temperature. This is in line 
with the mechanism of action of SV40T, which is known 
to interfere with Rb and p53 pathways thus driving cell 
proliferation [20]. Finally, the susceptibility of cells 
to undergo p53-mediated apoptosis at non-permissive 
temperature was confirmed using nutlin-3a, a compound 
that selectively induces p53 by inhibiting its degradation 
via Mdm2 [45, 46], suggesting normal p53 activity and 
apoptosis regulation at non-permissive temperature.  
We examined the presence of contact inhibition in 
ciPTEC-OAT1 for two reasons. Firstly, non-transformed 
epithelial cells are expected to be responsive to growth-
regulatory signals and undergo contact inhibition. Failure 
to display this would reflect cancerous cell behaviour 
and thus raise safety concerns [42]. Secondly, eyeing the 
potential use of ciPTEC-OAT1 in a BAK device [27], 
overgrowth of the cell monolayer could result in clogging 
of the tubules of the BAK device or affecting the epithelial 
barrier function. Our results showed that ciPTEC-OAT1 
undergo contact inhibition and do not grow beyond the 
expected monolayer, even when they are cultured for long 
periods of time at permissive temperature. The observed 
absence of multi-layered growth of ciPTEC-OAT1 could 
also be explained by the presence of a crowding-induced 
live cell extrusion mechanism that helps maintaining 
homeostatic cell numbers in the epithelium [47]. 
Employing a soft-agar assay, known to correlate 
closely to in vivo tumour-forming ability of cells [48], we 
demonstrated that ciPTEC-OAT1 do not proliferate in an 
anchorage-independent manner. Small colonies observed 
sporadically were not progressively growing and exceeding 
35 µm in diameter, indicating small cell clumps. In addition, 
we observed that the number of single cells present in the 
agarose at the beginning of the experiment decreased over 
the 4 weeks period of culturing, suggesting that some cells 
were dying, possibly due to anoikis [49]. However, this 
observation will be confirmed in future studies. In contrast 
to ciPTEC-OAT1, HeLa cells grew in absence of anchorage 
as described for cancer cell types [42]. 
Many assays have been described to study metastatic 
behaviour of malignant cells in vitro [50]. A requirement 
for metastasis is that cells are capable of invasion, i.e. 
migration through an ECM barrier in which movement 
is primarily limited to the cell’s ability to proteolytically 
degrade its surroundings, though amoeboid motility has 
also been reported depending on the (micro-)environment 
[51, 52]. Here, single ciPTEC-OAT1 cells were confined 
to a 3D environment that consisted of growth factor-
reduced Matrigel™, using FCS-containing complete 
medium as a chemoattractant. The majority of cells lacked 
signs of invasive behaviour, though in a small subset we 
observed mesenchymal cell-like movement during the 
24 h incubation. But studies have shown that this type of 
movement also plays an important role in tissue repair 
[53]. Furthermore, it should be emphasized that metastasis 
is a complex multi-step process, involving detachment 
from the cell bulk, intravasation into the systemic 
circulation, survival in a relatively harsh environment (e.g. 
lacking anchorage and presence of immune surveillance) 
and finally, extravasation into a distant tissue or organ 
[52]. No single in vitro assay fully recapitulates the 
complete chain of these events [50]. However, our in vivo 
results further support an absence of tumorigenic and 
metastatic potential of the cells. 
The transgenes integration mediated by retroviral 
transduction could potentially lead to cell transformation 
and oncogenesis [37, 54]. Understanding functional 
consequences of the viral integration of the SV40T gene, 
hTERT and SLC22A6 transgenes is far from trivial. In 
contrast to protein-coding sequences, the function of non-
coding DNA remains largely unknown and the annotation 
of regulatory elements is often based on predictive models. 
Ensembl’s Regulatory Build is a good example, taking into 
account epigenetic markers, transcription-factor binding 
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sites and DNase I hypersensitive sites (DHS), amongst other 
features, to define regulatory regions [55]. The limitations 
become clear when considering the integration site of 
BCL2L1, a gene involved in both pro- and anti-apoptotic 
signaling through its two protein isoforms, Bcl-xS and 
Bcl-xL [56]. The Regulatory Build categorizes this area 
as a promoter-flanking region, despite its location being 
approximately 27 kb downstream from the actual promoter. 
The activity of regulatory elements tends to be cell-type 
specific, which makes the impact estimation through an 
in-silico approach particularly challenging. Our results 
demonstrating that ciPTEC-OAT1 remain subjected to 
the intrinsic apoptosis pathway, of which Bcl2l1 is a key 
regulator [56], suggest that the viral insertion did not reduce 
the cell’s capacity to undergo apoptosis. Moreover, four 
out of six transgenes are integrated in the opposite DNA 
strand. A difference in orientation can cause transcription 
machineries to converge and collide, a process termed 
transcriptional interference (TI). This generally manifests 
itself in decreased transcript levels [57, 58]. However, this 
type of integration also has a protective effect as it allows the 
transgene to be spliced out, resulting in an intact messenger 
RNA (mRNA) of the endogenous gene [57]. On the other 
hand, the transgenes of which the orientation matches that of 
the endogenous gene, in case of BCL2L1 and EEA1, could 
potentially lead to premature halt of endogenous genes 
transcription due to the presence of a termination signal 
in the long-terminal repeats (LTRs) of the viral vectors, 
leading to a truncated transcript of the endogenous gene 
[38]. However, it should be noted that one healthy allele 
remained for each affected gene, possibly limiting the 
impact of integration. In support, we demonstrated an intact 
endocytotic capacity in ciPTEC-OAT1 proving the unaltered 
expression and function of EEA1. 
Karyotyping of ciPTEC-OAT1 at passages 52 and 
62 showed the presence of a growing subpopulation of 
near-tetraploid cells with various complex chromosomal 
aberrations. Through its interaction with Bub-1, a 
spindle assembly checkpoint protein, SV40T can 
breach genomic integrity and induce tetraploidy [59]. 
Although this interaction appears to be unnecessary for 
immortalization, it has been demonstrated to trigger 
oncogenic transformation [60]. While the latter seemed 
absent in ciPTEC-OAT1, chromosomal abnormalities 
could have been avoided [18]. Still, SV40T as a tool for 
immortalization requires additional scrutiny, warranting a 
case-by-case evaluation of its impact on the chromosomal 
stability. This is especially important from a clinical 
perspective, as chromosomal instability could affect safety 
characteristics of a cell line. The creation of a SV40T 
mutant (U19dl89-97tsA58) that lacks the interaction site 
with Bub-1 is a promising development [61]. 
WHO guidelines regarding cell-based therapies 
suggest that all cell types intended for therapeutic 
purposes should be genetically stable as otherwise they 
would impose a significant risk regarding cell function and 
tumorigenic potential [44]. It should be noted that ciPTEC-
OAT1 have previously undergone a rigorous functional 
assessment, showing that, at least from the functional 
perspective, cells remain stable over a wide range of 
passages [26]. Despite chromosomal aberrations, these 
cells differentiate in mature cell monolayers exhibiting 
mulitple PTEC-related functions, including epithelial 
barrier formation, protein uptake, vitamin D activation, 
and transport of uremic metabolites [26, 27, 62]. 
Further, in accordance to the WHO regulations [44], 
we addressed tumorigenic and oncogenic potential of 
ciPTEC-OAT1 in vivo. During the 5 months follow-up, 
our negative control group (vehicle control) confirmed 
the absence of spontaneous tumour formation. The 
guidelines also suggest that 90% of the animals within 
the positive control group should develop progressively 
growing tumours at the injection site. In all animals of the 
positive control group nodules appeared within the first 
week after HeLa cell injections, but only 50% of animals 
developed histologically and 60% PCR-confirmed HeLa 
derived tumours, indicating susceptibility of the animal 
model to grow tumour xenografts. Moreover, according 
to the guidelines, at least 20% of the animals within the 
test group should develop tumours in order to consider a 
particular cell type to be tumorigenic or oncogenic. Given 
that none of the animals developed tumours in the two test 
groups, we carefully conclude that in the athymic nude 
rat model, ciPTEC-OAT1 did not possess tumorigenic or 
oncogenic potential confirming our in vitro results. 
Finally, considering that possible clinical use of 
these cells would only be in a context of an extracorporeal 
medical device and not direct transplantation, the altered 
karyotype and rare events of invasion observed in vitro, 
provided proper cell function, should not pose an extreme 
safety threat. 
In conclusion, by showing that ciPTEC-OAT1 do 
not portray fundamental characteristics of oncogenically 
transformed cells, do not present negative consequences 
of viral transductions and genomic transgene integrations, 
such as insertional mutagenesis, nor possess tumorigenic 
capacity in vivo, the present study lays an important 
foundation towards validating the safety of a conditionally 
immortalized cell line for clinical application as cell-based 
renal replacement therapy.
MATERIALS AND METHODS
Materials
All reagents were obtained from Sigma-Aldrich 
(Zwijndrecht, the Netherlands) unless stated otherwise.
Cell culture
Parent cell line (ciPTEC) and its OAT1-
overexpressing derivate (ciPTEC-OAT1) were maintained 
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in culture as described previously [26]. Culture of 
HeLa cells (ECACC, cat. nr. 93021013) is described in 
Supplementary Detailed Methods. 
Western blot analysis of SV40T
Protein expression of SV40T was analysed by 
Western blotting as described [16] and in Supplementary 
Detailed Methods. 
Cell cycle analysis
Cells fixed in ice-cold 70% (v/v) ethanol were 
stained with 40 µg/mL propidium iodide (PI) solution for 
30 min and DNA content of >10 000 cells per condition 
was measured using FACSCanto II flow cytometer 
(BD Biosciences, San Jose, CA, USA), as described in 
Supplementary Detailed Methods.
Apoptosis evaluation
Cell viability and caspase-3/7 expression, 
as indicators of apoptosis, were determined using 
PrestoBlue® cell viability (Life Technologies, Paisly, UK) 
and CellEvent™ Caspase-3/7 Green detection (Invitrogen, 
Eugene, OR, USA) reagents, respectively, following 
manufacturer’s instructions. Details are reported in 
Supplementary Detailed Methods. 
Contact inhibition
Contact inhibition and multi-layered cell growth 
was determined by performing a z-stack imaging of 
Hoechst 33342 (1 µM) labelled cells by means of Cell 
Voyager 7000 (CV7000) confocal microscope (Yokogawa 
Electric Corporation, Tokyo, Japan). An ImageJ plugin 
was developed to quantify the surface area covered by cell 
multi-layers (Supplementary Method 1), as described in 
Supplementary Detailed Methods. 
CiPTEC-OAT1 culture on hollow fiber 
membranes
Cell proliferation in a 3D environment was assessed 
by culturing cells for 28 days on L-DOPA (2 mg/ml) and 
collagen IV (25 μg/ml) double-coated microPES hollow 
fiber membranes (HFM; Membrana GmbH, Wuppertal, 
Germany), as described previously [27, 63, 64] and in 
Supplementary Detailed Methods.
Soft agar assay
Colony-forming ability of cells in anchorage-
independent conditions was assayed in a similar manner as 
described by Borowicz et al. [41]. Procedure is described 
in Supplementary Detailed Methods. 
Single cell invasion assay
The invasion assay was based on the protocol 
described by Zaman et al. [51]. Cell tracking analysis was 
performed using Fiji’s TrackMate plugin to determine 
the speed of motion across acquisitions, as well as the 
average speed throughout the experiment [65, 66]. Cells 
having a speed of > 6 µm/h were classified as invasive. 
We manually validated this threshold for optimum 
discrimination between invasive and non-invasive cells. 
Inclusion and exclusion criteria were applied as previously 
described [51]. All data were processed in MySQL 5.6.17 
(Oracle, Redwood City, CA, USA). Procedure is described 
in Supplementary Detailed Methods.
Targeted locus amplification for viral integration 
sites
The ciPTEC-OAT1 cell line was stably transduced 
using three viral vectors [16, 26], warranting an 
investigation into the occurrence of cell behavior-altering 
insertional mutagenesis. Determination of the exact 
location of the integrated transgenes was performed by 
Cergentis B.V. (Utrecht, the Netherlands) using targeted 
locus-amplification (TLA) technology as described [67]. 
Data was analysed using Ensembl’s genome browser in 
conjunction with the regulatory build [55, 68]. To predict 
the functional consequences of the integration sites, the 
Ensembl Variant Effect Predictor was utilized [69].
Cytogenetic analysis
Metaphase spreads of ciPTEC-OAT1 were 
G-banded and analysed for abnormalities (Cell Guidance 
Systems, Cambridge, UK). Approximately 20 metaphase 
spreads were analysed per experiment. Sample preparation 
is described in Supplementary Detailed Methods. 
Endocytosis
Endocytosis was evaluated by evaluating early 
endosome antigen (EEA1) expression and bovine serum 
albumin (BSA) uptake, similarly to [70] and reported in 
Supplementary Detailed Methods. 
Tumorigenicity and oncogenicity evaluation in 
vivo
Animal procedures were approved by the Ethics 
Committee of Animal Research of Utrecht University, 
Utrecht, The Netherlands (CCD approval number 
AVD108002017879). Male (n = 20; 4 weeks old, 
weighing between 103 and 172 g) and female (n = 20; 
4 weeks old, weighing between 94 and 133 g) athymic 
nude rats (Hsd:RH-Foxn1rnu; Envigo, Horst, Netherlands) 
were maintained in the Central Laboratory Animal 
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Research Facility (GDL, Utrecht, Netherlands), and 
housed in individually ventilated cage units at RT under 
a 12 h light/dark cycle. Food and water were provided ad 
libitum. All animals were treated according to IVD and 
CCD guidelines and all efforts were made to minimize 
suffering. Animals were euthanized by pentobarbital 
(Faculty of Veterinary Medicine, Utrecht, the Netherlands) 
overdose via intraperitoneal injection, followed by cervical 
dislocation as soon as animals became unconscious. 
Details are reported in Supplementary Detailed Methods. 
Histopathological analysis
First, formalin-fixed tissues and organs were 
examined macroscopically for presence of abnormalities. 
Afterwards, formalin-fixed tissues were subjected to 
further microscopical histological analysis as described 
[71, 72]. Examination was performed by board-certified 
veterinary pathologists of the Dutch Molecular Pathology 
Centre (Department of Pathobiology, Faculty of Veterinary 
Medicine, Utrecht, the Netherlands). Representative 
images were taken using Olympus BX45 microscope 
equipped with DP25 camera (Leiderdorp, the Netherlands) 
with 2× magnification. 
DNA extraction and PCR analysis 
Human origin of observed tumors was confirmed 
by detection of human specific Alu elements [73], using 
Real-Time PCR, following manufacturer’s instructions. 
Details regarding sample preparation, reaction protocol 
and primers used are described in Supplementary Detailed 
Methods. 
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA), 
unless stated otherwise. Data are presented as mean ± 
standard error of the mean (SEM) of three independent 
experiments performed in triplicate, unless stated 
otherwise. Significance was evaluated using the unpaired 
two-tailed Student’s t-test or one-way ANOVA followed 
by Dunnett’s multiple comparison test where appropriate. 
P-values < 0.05 were considered as significant. Where 
appropriate, significance is denoted as *(p < 0.05), **(p < 
0.01) and ***(p < 0.001).
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